How Nemifitide diTFA can Save You Time, Stress, and Money.
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage several intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Key demo aims were To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, when one